[et_pb_section fb_built=”1″ _builder_version=”3.22.7″ custom_padding=”||5px|||”][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” _builder_version=”3.22.3″ custom_padding=”24px|0px|25px|0px|false|false”][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”3.25″][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_blurb title=”Editoral in Hungarian ” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/szerklevl%20bereczki%20web.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/szerklevl bereczki web.pdf” link_option_url_new_window=”on”]<\/p>\n
D\u00e1niel Bereczki<\/p>\n
[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”3.22.7″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n
A neurol\u00f3giai betegs\u00e9gek ter\u00e9n az elm\u00falt id\u0151szakban sz\u00e1mos \u00faj kezel\u00e9si elj\u00e1r\u00e1s terjedt el. Idetartozik a m\u00e9lyagyi stimul\u00e1ci\u00f3 mozg\u00e1szavarokban \u00e9s f\u00e1jdalomszindr\u00f3m\u00e1kban; a sz\u00e1m\u00edt\u00f3g\u00e9p-vez\u00e9relt levodopa adagol\u00e1s gasztroszt\u00f3m\u00e1s kat\u00e9teren (\u201eduodopa\u201d) Parkinson-k\u00f3rban; a nervus vagus elektromos stimul\u00e1c\u00f3ja epilepszia kezel\u00e9s\u00e9re; a mechanikus thrombekt\u00f3mia akut iszk\u00e9mi\u00e1s stroke-ban; a gamma-k\u00e9s bevezet\u00e9se k\u00f6zponti idegrendszeri daganatok kezel\u00e9s\u00e9re; elektromos gerincvel\u0151stimul\u00e1ci\u00f3 \u00e9s mechanikus szerkezetek \u2013 \u201erobotok\u201d \u2013 alkalmaz\u00e1sa gerincvel\u0151 s\u00e9r\u00fcl\u00e9s ut\u00e1n stb. Ezen l\u00e1tv\u00e1nyos, invaz\u00edv, eszk\u00f6z\u00f6s beavatkoz\u00e1sok mellett tal\u00e1n kevesebb figyelem ir\u00e1nyult a farmakoter\u00e1pi\u00e1s ter\u00fcleteken bek\u00f6vetkezett fejl\u0151d\u00e9sre, pedig a neurol\u00f3giai betegs\u00e9gek gy\u00f3gyszeres kezel\u00e9s\u00e9ben az elm\u00falt id\u0151szakban t\u00f6rt\u00e9nt n\u00e9h\u00e1ny jelent\u0151s v\u00e1ltoz\u00e1s, illetve el\u0151rel\u00e9p\u00e9s.<\/p>\n
A cerebrovaszkul\u00e1ris betegs\u00e9gek ter\u00e9n a legjelent\u0151sebb a sz\u00f6veti plazminog\u00e9n aktiv\u00e1torral (rtPA) v\u00e9gzett intrav\u00e9n\u00e1s thrombol\u00edzis alkalmaz\u00e1si el\u0151irat\u00e1ban 2012 tavasz\u00e1n bek\u00f6vetkezett v\u00e1ltoz\u00e1s.\u00a0Akut iszk\u00e9mi\u00e1s stroke<\/strong><\/em>-ban a kor\u00e1bbi 3 \u00f3r\u00e1s id\u0151ablak 4,5 \u00f3r\u00e1ra terjeszt\u00e9se egy nagy randomiz\u00e1lt, kontroll\u00e1lt vizsg\u00e1lat (ECASS-3), valamint a mindennapi gyakorlatot k\u00f6vet\u0151, t\u00f6bb ezer beteg adat\u00e1t tartalmaz\u00f3 adatb\u00e1zis (az \u00fan. SITS-MOST adatb\u00e1zis) alapj\u00e1n t\u00f6rt\u00e9nt. Mindk\u00e9t vizsg\u00e1lat igazolta, hogy a sz\u00f6veti plazminog\u00e9n aktiv\u00e1torral t\u00f6rt\u00e9nt thrombol\u00edzis nemcsak biztons\u00e1gos, hanem hat\u00e9kony is a 3 – 4,5 \u00f3r\u00e1s id\u0151ablak alkalmaz\u00e1sakor. Hangs\u00falyozni kell azonban, hogy min\u00e9l hamarabb sor ker\u00fcl a kezel\u00e9sre, az ann\u00e1l hat\u00e9konyabb. A SITS-MOST adatb\u00e1zis, illetve egy\u00e9b megfigyel\u00e9sek alapj\u00e1n az is egy\u00e9rtelm\u0171v\u00e9 v\u00e1lt, hogy a thrombol\u00edzis a 80 \u00e9v f\u00f6l\u00f6tti korcsoportban ugyanolyan hat\u00e9kony, \u00e9s nem kev\u00e9sb\u00e9 biztons\u00e1gos, mint a fiatalabb korcsoportban. Sajn\u00e1latos m\u00f3don az \u00faj alkalmaz\u00e1si el\u0151iratban mindezek ellen\u00e9re v\u00e1ltozatlanul benne maradt a 80 \u00e9ves \u00e9letkor f\u00f6l\u00f6tti alkalmaz\u00e1s ellenjavallata. A 2012-es alkalmaz\u00e1si el\u0151iratban szerepel t\u00f6bb egy\u00e9b olyan kik\u00f6t\u00e9s is, mely a szakmai szervezetek v\u00e9lem\u00e9nye szerint sz\u00fcks\u00e9gtelen\u00fcl korl\u00e1tozza azon betegek k\u00f6r\u00e9t, akikn\u00e9l az iszk\u00e9mi\u00e1s stroke egyetlen oki kezel\u00e9se, a thrombol\u00edzis jelenleg alkalmazhat\u00f3 lenne. Az id\u0151ablak tov\u00e1bbi kitol\u00e1s\u00e1t 6 \u00f3r\u00e1ra, illetve a 80 \u00e9vn\u00e9l id\u0151sebbekn\u00e9l val\u00f3 alkalmazhat\u00f3s\u00e1g k\u00e9rd\u00e9s\u00e9t is vizsg\u00e1lja a k\u00f6zelm\u00faltban lez\u00e1rult, 3000 beteget randomiz\u00e1l\u00f3 IST-3 vizsg\u00e1lat \u2013 ennek eredm\u00e9nyeit hivatalosan az Eur\u00f3pai Stroke Konferenci\u00e1n, 2012. m\u00e1jus v\u00e9g\u00e9n ismertett\u00e9k.<\/p>\n A cerebrovaszkul\u00e1ris betegs\u00e9gek kezel\u00e9s\u00e9ben az akut kezel\u00e9sen t\u00fal az\u00a0els\u0151dleges, illetve m\u00e1sodlagos stroke prevenci\u00f3<\/strong><\/em>\u00a0ter\u00fclet\u00e9n is fontos v\u00e1ltoz\u00e1st jelent az \u00faj antikoagul\u00e1nsok hozz\u00e1f\u00e9rhet\u0151s\u00e9ge. A direkt thrombin inhibitor dabigatran \u00e9s a X. faktor inhibitorok (rivaroxaban, apixaban) m\u00e1r jelenleg is hozz\u00e1f\u00e9rhet\u0151ek a magyar klinikai gyakorlat sz\u00e1m\u00e1ra is. A k\u00e9sz\u00edtm\u00e9nyek a kor\u00e1bbi K-vitamin antagonist\u00e1kn\u00e1l j\u00f3val kevesebb vesz\u00e9ly mellett \u00e9s azonos hat\u00e9konys\u00e1ggal adhat\u00f3k a cerebrovaszkul\u00e1ris betegs\u00e9gek megel\u0151z\u00e9s\u00e9re pitvafibrill\u00e1ci\u00f3ban, nincsen jelent\u0151s ismert gy\u00f3gyszerinterakci\u00f3juk, nem ig\u00e9nyelnek speci\u00e1lis \u00e9trendet \u00e9s nem ig\u00e9nyelnek rendszeres v\u00e9ralvad\u00e1s (INR) ellen\u0151rz\u00e9st sem.\u00a0 Ezen gy\u00f3gyszerek mindennapi gyakorlatba ker\u00fcl\u00e9s\u00e9t g\u00e1tolja, hogy t\u00e1mogat\u00e1ssal m\u00e9g nem rendelkeznek \u00e9s a havi adag betegenk\u00e9nt teljes \u00e1ron k\u00f6zel 30 ezer Ft kiad\u00e1st jelent.<\/p>\n \u00daj gy\u00f3gyszeres kezel\u00e9si lehet\u0151s\u00e9gek az elm\u00falt \u00e9vekben a szkler\u00f3zis multiplex, az epilepszia \u00e9s a Parkinson-k\u00f3r kezel\u00e9s\u00e9ben is lehet\u0151v\u00e9 v\u00e1ltak.<\/p>\n A\u00a0szkler\u00f3zis multiplex<\/strong><\/em>\u00a0ter\u00e9n az elm\u00falt \u00e9vek egyik nagy eredm\u00e9nye egy monoklon\u00e1lis ellenanyag-k\u00e9sz\u00edtm\u00e9ny (natalizumab) bevezet\u00e9se volt, mely Magyarorsz\u00e1gon is alkalmazhat\u00f3, speci\u00e1lis felt\u00e9telek mellett, n\u00e9gyhetente ism\u00e9telve, inf\u00fazi\u00f3ban. Hasonl\u00f3an monoklon\u00e1lis ellenanyag a szkler\u00f3zis multiplex kezel\u00e9s\u00e9re bevezetett rituximab \u00e9s alemtuzumab. Az elm\u00falt \u00e9vek \u00faj ir\u00e1nya a per os k\u00e9sz\u00edtm\u00e9nyek kifejleszt\u00e9se. Jelenleg k\u00f6zel sz\u00e1z molekula vizsg\u00e1lata folyik. N\u00e9h\u00e1ny vizsg\u00e1lat m\u00e1r befejez\u0151d\u00f6tt, \u00e9s a cladribin, a fingolimod, a dalfampridin \u00e9s a teriflunomid olyan k\u00e9sz\u00edtm\u00e9nyek, melyek m\u00e1r jelen vannak, vagy a k\u00f6zelj\u00f6v\u0151ben el\u00e9rhet\u0151ek lesznek a klinikai gyakorlat sz\u00e1m\u00e1ra is. A fingolimod m\u00e1r jelenleg is a hazai ter\u00e1pi\u00e1s fegyvert\u00e1r r\u00e9sze.<\/p>\n Az\u00a0epilepszia<\/strong><\/em>\u00a0kezel\u00e9s\u00e9re sz\u00e1mos hat\u00e9kony farmakoter\u00e1pi\u00e1s k\u00e9sz\u00edtm\u00e9ny \u00e1ll rendelkez\u00e9sre, ez\u00e9rt monoter\u00e1pi\u00e1ban placebo-kontroll\u00e1lt vizsg\u00e1latokat nem v\u00e9geznek. Jelenleg (2012. m\u00e1jus) t\u00f6bb mint 240 klinikai vizsg\u00e1lat folyik epilepszia indik\u00e1ci\u00f3ban. A farmakoter\u00e1pi\u00e1s klinikai vizsg\u00e1latok \u00e1ltal\u00e1ban\u00a0 ter\u00e1piarezisztens, fok\u00e1lis epilepsz\u00e1ban (pl. tempor\u00e1lis epilepszia) szenved\u0151 betegek kezel\u00e9s\u00e9nek kieg\u00e9sz\u00edt\u00e9s\u00e9re tervezett, add-on k\u00e9sz\u00edtm\u00e9nyek vizsg\u00e1lat\u00e1ra ir\u00e1nyulnak. A sz\u0171k bev\u00e9teli krit\u00e9riumok nehez\u00edtik a betegbevon\u00e1st ezen vizsg\u00e1latokba. Az ut\u00f3bbi id\u0151ben t\u00f6bbek k\u00f6z\u00f6tt ezogabinnal, eslicarbazepinnel, brivaracetammal, zonisamiddal \u00e9s lacosamiddal folynak farmakoter\u00e1pi\u00e1s vizsg\u00e1latok, illetve a m\u00e1r kor\u00e1bban bevezetett k\u00e9sz\u00edtm\u00e9nyek hat\u00e1s\u00e1t elemzik pontosabban k\u00f6r\u00fcl\u00edrt betegcsoportokban (pl. gyermekekben, halmozott rohamokban, stb). Folynak direkt gy\u00f3gyszer-\u00f6sszehasonl\u00edt\u00e1sok monoter\u00e1pi\u00e1ban, d\u00f3zispontos\u00edt\u00f3 vizsg\u00e1latok, valamint parenter\u00e1lis formul\u00e1ci\u00f3k kipr\u00f3b\u00e1l\u00e1s\u00e1ra is van p\u00e9lda.<\/p>\n Parkinson-k\u00f3rban<\/strong><\/em>\u00a0jelenleg t\u00f6bb mint 300 klinikai vizsg\u00e1latba vonnak be betegeket vil\u00e1gszerte. A vizsg\u00e1latok r\u00e9szint a Parkinson-k\u00f3r alapt\u00fcneteire vagy egy-egy j\u00f3l k\u00f6r\u00fcl\u00edrt t\u00fcnetre (pl. freezing, egyens\u00falyzavar), r\u00e9szint a k\u00eds\u00e9r\u0151 t\u00fcnetekre (pl. depresszi\u00f3, kognit\u00edv t\u00fcnetek, f\u00e1rad\u00e9konys\u00e1g, alv\u00e1szavar) ir\u00e1nyulnak. T\u00f6bb vizsg\u00e1lat a gy\u00f3gyszerkombin\u00e1ci\u00f3k hat\u00e1soss\u00e1g\u00e1t elemzi.<\/p>\n Az\u00a0\u00faj gy\u00f3gyszerformul\u00e1ci\u00f3k<\/strong><\/em>\u00a0k\u00f6z\u00f6tt megeml\u00edtend\u0151k a tapaszok (\u201epatch\u201d). Az ilyen formul\u00e1ci\u00f3k c\u00e9lja vagy a lok\u00e1lis hat\u00e1s, vagy pedig a folyamatos felsz\u00edv\u00f3d\u00e1sb\u00f3l ered\u0151 egyenletes v\u00e9rszint biztos\u00edt\u00e1sa. Az el\u0151bbire p\u00e9lda az elm\u00falt h\u00f3napokban forgalomba ker\u00fclt kapszaicin tapasz, mely lok\u00e1lis f\u00e1jdalom kezel\u00e9s\u00e9re (pl. posztherpeszes neuralgia) alkalmazhat\u00f3. Mivel a k\u00e9sz\u00edtm\u00e9ny viszonylag magas koncentr\u00e1ci\u00f3ban tartalmaz kapszaicint, csak megfelel\u0151en kik\u00e9pzett centrumokban, a biztons\u00e1gi el\u0151\u00edr\u00e1sok betart\u00e1sa \u00e9s v\u00e9d\u0151felszerel\u00e9s haszn\u00e1lata mellett javasolhat\u00f3 az alkalmaz\u00e1sa. A tapasz 30-60 percig marad a b\u0151r\u00f6n, a kezel\u00e9s h\u00e1romhavonta ism\u00e9telhet\u0151.<\/p>\n A tapasz formul\u00e1ci\u00f3 m\u00e1sik c\u00e9lja lehet az egyenletes gy\u00f3gyszerszint biztos\u00edt\u00e1sa. Erre p\u00e9lda a Parkinson-k\u00f3rban alkalmazott dopamin-agonista rotigotin, vagy az Alzheimer-k\u00f3rban alkalmazhat\u00f3 rivastigmin. Mindk\u00e9t k\u00e9sz\u00edtm\u00e9ny hozz\u00e1f\u00e9rhet\u0151 haz\u00e1nkban is.<\/p>\n A fentiek alapj\u00e1n teh\u00e1t elmondhat\u00f3, hogy a k\u00f6zponti \u00e9s perif\u00e9ri\u00e1s idegrendszeri betegs\u00e9gek farmakoter\u00e1pi\u00e1ja ter\u00e9n az elm\u00falt \u00e9vekben sz\u00e1mos \u00faj k\u00e9sz\u00edtm\u00e9ny ker\u00fclt forgalomba \u00e9s a jelenleg foly\u00f3 nagysz\u00e1m\u00fa vizsg\u00e1lat alapj\u00e1n feltehet\u0151en a k\u00f6vetkez\u0151 \u00e9vekben is v\u00e1rhat\u00f3 \u00faj k\u00e9sz\u00edtm\u00e9nyek megjelen\u00e9se Magyarorsz\u00e1gon is.<\/p>\n<\/div>\n [\/et_pb_toggle][et_pb_blurb title=”Additional psychometric data for the DS1K mood questionnaire Experience from a large sample study involving parents of young children” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/danis%20web.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/danis web.pdf” link_option_url_new_window=”on”]<\/p>\n Ildik\u00f3 Danis, No\u00e9mi Scheuring, Eszter\u00a0 Papp and Antal Czinner<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n Aims: A new instrument for assessing depressive mood, the first version of Depression Scale <\/span><\/p>\n (Neuropsychopharmacol Hung 2012; 14(2): 79-85; doi: 10.5706\/nph201206001)<\/em><\/p>\n Keywords<\/strong>: Screening of depression, DS1K, For Healthy Offspring Project, psychometric analysis<\/p>\n<\/div>\n [\/et_pb_toggle][et_pb_blurb title=”Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/weizman%20web.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/weizman web.pdf” link_option_url_new_window=”on”]<\/p>\n Shira Weizman, Xenia Gonda, Peter Dome and Gabor Faludi<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n Major depressive disorder is one of the most prevalent psychiatric disorders, and in spite of extensive ongoing research, we neither fully understand its etiopathological background, nor do we possess sufficient pharmacotherapeutic tools to provide remission for all patients. Depression is a heterogenous phenomenon both in its manifestation and its biochemical and genetic background with multiple systems involved. Similarly, the employed pharmaceutical agents in the treatment of depression also effect multiple neurotransmitter systems in the brain. However, we do not yet possess sufficient tools to be able to choose the medication that treats the symptoms most effectively while contributing to minimal side effects in parallel and thus provide personalized pharmacotherapy for depression. In the present paper we review genetic polymorphisms that may be involved in the therapeutic effects and side effects of antidepressive medications and which, in the future, may guide customized selection of the pharmacotherapeutic regimen in case of each patient.<\/span><\/p>\n <\/span><\/p>\n (Neuropsychopharmacol Hung 2012; 14(2): 87-101; doi: 10.5706\/nph201206002)<\/em><\/p>\n Keywords:<\/strong> pharmacogenetics, antidepressants, major depressive disorder, polymorphisms<\/p>\n<\/div>\n [\/et_pb_toggle][et_pb_blurb title=”Second generation antipsychotics in the treatment of affective disorders \u2013 review of the literature” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/vrs%20web.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/vrs web.pdf” link_option_url_new_window=”on”]<\/p>\n Viktor V\u00f6r\u00f6s<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”3.22.7″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n (<\/em>Neuropsychopharmacol Hung 2012; 14(2): 103-112; doi: 10.5706\/nph201206003)<\/em><\/p>\n Keywords<\/strong>: second generation antipsychotics, affective disorders, quetiapine<\/p>\n<\/div>\n [\/et_pb_toggle][et_pb_blurb title=”The European Psychiatric Association (EPA) guidance on suicide treatment and prevention” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/ngyilkossg%20kezelsi%20tmutat%20web.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/ngyilkossg kezelsi tmutat web.pdf” link_option_url_new_window=”on”]<\/p>\n Danuta Wasserman, Zoltan Rihmer, Dan Rujescu, Marco Sarchiapone, Marcus Sokolowski, David Titelman, Gil Zalsman, Zvi Zemishlany \u00e9s Vladimir Carli<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n Suicide is a major public health problem in the WHO European Region accounting for over This article was originally published as: Wasserman D., Rihmer Z., Rujescu D., Sarchiapone M.,<\/em> <\/em><\/p>\n (Neuropsychopharmacol Hung 2012; 14(2): 113-136; doi: 10.5706\/nph201206004)<\/em><\/p>\n Keywords<\/strong>: suicide, depression, psychiatric diagnosis, prevention, identification, treatment<\/p>\n<\/div>\n [\/et_pb_toggle][et_pb_blurb title=”Designer drug induced psychosis” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/fullajtr%20web.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-2-szam\/fullajtr web.pdf” link_option_url_new_window=”on”]<\/p>\n M\u00e1t\u00e9\u00a0 Fullajt\u00e1r and Csaba Ferencz<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n 3,4-methylene-dioxy-pyrovalerone (MDPV) is a popular designer drug in Hungary, known as <\/span><\/p>\n (Neuropsychopharmacol Hung 2012; 14(2): 137-140; doi: 10.5706\/nph201206005)<\/em><\/p>\n Keywords<\/strong>: MDPV, MP4, drug-induced psychosis, delirium<\/p>\n<\/div>\n [\/et_pb_toggle][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/05\/cimlap_2012_junius_web_kicsi.jpg” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” _builder_version=”3.23″ box_shadow_style=”preset3″][\/et_pb_image][\/et_pb_column][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" VOLUME 14, ISSUE 2, JUNE 2012D\u00e1niel Bereczki A neurol\u00f3giai betegs\u00e9gek ter\u00e9n az elm\u00falt id\u0151szakban sz\u00e1mos \u00faj kezel\u00e9si elj\u00e1r\u00e1s terjedt el. Idetartozik a m\u00e9lyagyi stimul\u00e1ci\u00f3 mozg\u00e1szavarokban \u00e9s f\u00e1jdalomszindr\u00f3m\u00e1kban; a sz\u00e1m\u00edt\u00f3g\u00e9p-vez\u00e9relt levodopa adagol\u00e1s gasztroszt\u00f3m\u00e1s kat\u00e9teren (\u201eduodopa\u201d) Parkinson-k\u00f3rban; a nervus vagus elektromos stimul\u00e1c\u00f3ja epilepszia kezel\u00e9s\u00e9re; a mechanikus thrombekt\u00f3mia akut iszk\u00e9mi\u00e1s stroke-ban; a gamma-k\u00e9s bevezet\u00e9se k\u00f6zponti idegrendszeri daganatok kezel\u00e9s\u00e9re; […]<\/p>\n","protected":false},"author":4,"featured_media":48318,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[63],"project_tag":[],"class_list":["post-49326","project","type-project","status-publish","has-post-thumbnail","hentry","project_category-2012-en"],"_links":{"self":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/comments?post=49326"}],"version-history":[{"count":8,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49326\/revisions"}],"predecessor-version":[{"id":49694,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49326\/revisions\/49694"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media\/48318"}],"wp:attachment":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media?parent=49326"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_category?post=49326"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_tag?post=49326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Questionnaire (DS1K) was published in 2008 by Halmai et al. This scale was used in our large
sample study, in the framework of the For Healthy Offspring project, involving parents of
young children. The original questionnaire was developed in small samples, so our aim was
to assist further development of the instrument by the psychometric analysis of the data
in our large sample (n=1164). Method: The DS1K scale was chosen to measure the parents\u2019
mood and mental state in the For Healthy Offspring project. The questionnaire was completed
by 1063 mothers and 328 fathers, yielding a heterogenous sample with respect to age and
socio-demographic status. Analyses included main descriptive statistics, establishing the
scales\u2019 inner consistency and some comparisons. Results were checked in our original and
multiple imputed datasets as well. Results: According to our results the reliability of our scale
was much worse than in the original study (Cronbach alpha: 0.61 versus 0.88). During the
detailed item-analysis it became clear that two items contributed to the observed decreased
coherence. We assumed a problem related to misreading in case of one of these items. This
assumption was checked by cross-analysises by the assumed reading level. According to our
results the reliability of the scale was increased in both the lower and higher education level
groups if we did not include one or both of these problematic items. However, as the number
of items decreased, the relative sensitivity of the scale was also reduced, with fewer persons
categorized in the risk group compared to the original scale. Conclusion: We suggest for the
authors as an alternative solution to redefine the problematic items and retest the reliability
of the measurement in a sample with diverse socio-demographic characteristics.\u00a0<\/span><\/p>\n
affective disorders. The treatment of major depressive disorders and the acute and long-term
treatment of bipolar affective disorders are also discussed. After the special role of quetiapine
is highlighted, a novel psychopharmacological terminology and nomenclature are also
introduced..<\/p>\n
150,000 deaths per year. Suicidal crisis: Acute intervention should start immediately in order
to keep the patient alive. Diagnosis: An underlying psychiatric disorder is present in up to 90%
of people who completed suicide. Comorbidity with depression, anxiety, substance abuse and
personality disorders is high. In order to achieve successful prevention of suicidality, adequate
diagnostic procedures and appropriate treatment for the underlying disorder are essential.
Treatment: Existing evidence supports the efficacy of pharmacological treatment and cognitive behavioural therapy (CBT) in preventing suicidal behaviour. Some other psychological
treatments are promising, but the supporting evidence is currently insufficient. Studies show
that antidepressant treatment decreases the risk for suicidality among depressed patients.
However, the risk of suicidal behaviour in depressed patients treated with antidepressants
exists during the first 10\u201314 days of treatment, which requires careful monitoring. Short-term
supplementary medication with anxiolytics and hypnotics in the case of anxiety and insomnia
is recommended. Treatment with antidepressants of children and adolescents should only be
given under supervision of a specialist. Long-term treatment with lithium has been shown
to be effective in preventing both suicide and attempted suicide in patients with unipolar
and bipolar depression. Treatment with clozapine is effective in reducing suicidal behaviour
in patients with schizophrenia. Other atypical antipsychotics are promising but more evidence is required. Treatment team: Multidisciplinary treatment teams including psychiatrist
and other professionals such as psychologist, social worker, and occupational therapist are
always preferable, as integration of pharmacological, psychological and social rehabilitation
is recommended especially for patients with chronic suicidality. Family: The suicidal person
independently of age should always be motivated to involve family in the treatment. Social
support: Psychosocial treatment and support is recommended, as the majority of suicidal
patients have problems with relationships, work, school and lack functioning social networks.
Safety: A secure home, public and hospital environment, without access to suicidal means is
a necessary strategy in suicide prevention. Each treatment option, prescription of medication
and discharge of the patient from hospital should be carefully evaluated against the involved
risks. Training of personnel: Training of general practitioners (GPs) is effective in the prevention of suicide. It improves treatment of depression and anxiety, quality of the provided care
and attitudes towards suicide. Continuous training including discussions about ethical and
legal issues is necessary for psychiatrists and other mental health professionals.<\/span><\/p>\n
Sokolowski M., Titelman D., et al. The European Psychiatric Association (EPA) guidance on suicide<\/em>
treatment and prevention. European Psychiatry 2012;27(2):129-141. doi:10.1016\/j.eurpsy.<\/em>
2011.06.003 Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved. With permission.<\/em><\/p>\n
MP4. We present a case of a 34-year-old man, whose first psychotic episode was observed in
the presence of MP4 use. The paranoid ideas of reference and the dereistic thinking could be
the consequence of drug-induced psychosis. Within 24 hours after the intoxication was over
delirium set in. The patient\u2019s history included only the use of MP4, use of other kinds of drugs
was negated. The drug tests were negative, amphetamine derivates were not detectable in
the urine sample. It is most likely that the MP4 pill contained an amount of MDPV less than
detectable. In conclusion we suggest that the clinical picture could be the consequence of
regular MDPV use.<\/span><\/p>\n